Automated High-Efficiency Screening Platform for Antibody Selection and Functional Assays

Our high throughput capabilities provides TopAlliance with a foundation for our R&D of innovative monoclonal antibodies and functional screening in vitro and in vivo.  We have developed a suite of unique cell lines expressing our desired drug targets along with proprietary assays, humanization capabilities and model systems to accelerate our understanding of target biology, function and mechanism of action.

Our systematic research process enables us to rapidly identify our drug candidate of interest to advance towards clinical development.

Our high throughput capabilities provides TopAlliance with a foundation for our R&D of innovative monoclonal antibodies and functional screening in vitro and in vivo.  We have developed a suite of unique cell lines expressing our desired drug targets along with proprietary assays, humanization capabilities and model systems to accelerate our understanding of target biology, function and mechanism of action.

Our systematic research process enables us to rapidly identify our drug candidate of interest to advance towards clinical development.

T-cell Engaging Antibody Circuits (TEAC) Platform – Enhancing our Antibody Therapies

Partnership with Revitope

Tumors typically do not express cell surface proteins unique to the tumor, conventional bispecific antibody therapeutics can generate unwanted and substantial “on-target, off-tumor” toxicity. Revitope’s two-component T-cell engaging antibody circuits are designed to permit specific recruitment and activation of T-cells exclusively by tumor cells, thereby reducing systemic toxicity.

Though developed with traditional tumor targeting domains, TEAC therapies split the CD3 paratope (the T-cell recognition domain) into two halves, with one half on one molecule and the other half on the other molecule. This allows for true dual-antigen targeting to a unique tumor-specific address – two inputs coming together to enable one precision targeted output. Only when the two molecules come together through binding to their different tumor targets on the same tumor cell can the two halves of the CD3 binding domain recombine and create a fully functional anti-CD3 domain (a TEAC).

Scientific Publications

Read More

Company Publications

Read More